Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
IPO Year: 2021
Exchange: AMEX
Website: brooklynitx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/29/2021 | $9.00 | Overweight | Cantor Fitzgerald |
| 10/6/2021 | $20.00 | Buy | Maxim Group |
SC TO-I - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)
DEF 14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
DEFA14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
N-CEN - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
DEF 14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
N-CSR - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
424B3 - Eterna Therapeutics Inc. (0000748592) (Filer)
EFFECT - Eterna Therapeutics Inc. (0000748592) (Filer)
8-K - Eterna Therapeutics Inc. (0000748592) (Filer)
3 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00
Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00